SynAct Pharma AB (STO:SYNACT)

Sweden flag Sweden · Delayed Price · Currency is SEK
19.00
-0.70 (-3.55%)
Mar 2, 2026, 5:24 PM CET
Market Cap1.01B +31.9%
Revenue (ttm)n/a
Net Income-110.83M
EPS-2.17
Shares Out53.12M
PE Ration/a
Forward PE5.05
Dividendn/a
Ex-Dividend Daten/a
Volume127,638
Average Volume137,302
Open19.40
Previous Close19.70
Day's Range18.66 - 19.50
52-Week Range13.40 - 25.30
Beta1.06
RSI40.76
Earnings DateFeb 18, 2026

About SynAct Pharma AB

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases.... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 8
Stock Exchange Nasdaq Stockholm
Ticker Symbol SYNACT
Full Company Profile

Financial Performance

Financial Statements